Simon Lord Selected Research

Neoplasms (Cancer)

11/2022	Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications.
1/2022	VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.
10/2021	First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
1/2021	Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
1/2021	Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits.
1/2019	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.
1/2019	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
4/2018	Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.
8/2016	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.
1/2016	Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon Lord Research Topics

Disease

11	Neoplasms (Cancer) 11/2022 - 08/2011
5	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2010
3	Hypoxia (Hypoxemia) 01/2019 - 08/2011
2	Disease Progression 01/2021 - 01/2019
1	Cardiotoxicity 01/2022
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Heart Failure 01/2022
1	Inflammation (Inflammations) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Left Ventricular Dysfunction 01/2022
1	Hypersensitivity (Allergy) 01/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2021
1	Frailty 01/2021
1	Skin Neoplasms (Skin Cancer) 01/2021
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2015
1	Carcinogenesis 10/2014

Drug/Important Bio-Agent (IBA)

2	Adenosine Triphosphate (ATP)IBA 11/2022 - 10/2014
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2011
2	Pharmaceutical PreparationsIBA 10/2021 - 01/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 08/2016
2	Hormones (Hormone)IBA 01/2019 - 01/2019
1	candesartanIBA 01/2022
1	Carvedilol (Coreg)FDA LinkGeneric 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	TroponinIBA 01/2022
1	AnthracyclinesIBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Troponin IIBA 01/2022
1	Gadolinium DTPA (Magnevist)FDA Link 01/2022
1	Designed Ankyrin Repeat ProteinsIBA 10/2021
1	MP0250IBA 10/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	berzosertibIBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	VX (EDIM)IBA 01/2021
1	PlatinumIBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	3' Untranslated Regions (3' UTR)IBA 01/2021
1	P-2 (P 2)IBA 01/2021
1	Glutamine (L-Glutamine)FDA Link 01/2019
1	Estrogen ReceptorsIBA 01/2019
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2019
1	Fulvestrant (Faslodex)FDA Link 01/2019
1	Ado-Trastuzumab EmtansineIBA 01/2019
1	Amino Acids FDA Link 01/2019
1	trastuzumab duocarmazineIBA 01/2019
1	Bevacizumab (Avastin)FDA Link 08/2016
1	Oxygen (Dioxygen)IBA 01/2016
1	fibrin fragment D (D-dimer)IBA 01/2015
1	Imatinib Mesylate (Gleevec)FDA Link 01/2015
1	Perilipin-2IBA 10/2014
1	Fatty Acids (Saturated Fatty Acids)IBA 10/2014
1	GlycogenIBA 10/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2014
1	LipidsIBA 10/2014
1	MicroRNAs (MicroRNA)IBA 08/2011

Therapy/Procedure

8	Therapeutics 11/2022 - 12/2010
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2021
1	Intravenous Administration 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Neoadjuvant Therapy 08/2016